Thyroid Flashcards
Least involved level in thyroid ca
Va
RLN which arch
6 th
Rt non rec ln
1%
Features suggestive of malignancy thyroid
Taller than wide
Micro calcification
Rim calcificat
Irregular margins
Cect done when in thyroid ca
Local Advanced ca or with cord paresis
Indications for total
thyroidectomy or lobectomy, if all
..No prior radiation exposure
• No distant metastases
• No lateral cervical lymph node
metastases
D
• No extrathyroidal extension
Tumor 1-4 cm in diameter
]Indications for total
thyroidectomy (any present):
• Known distant metastases
• Extrathyroidal extension
• Tumor >4 cm in diameter
• Lateral cervical lymph node
metastases or gross central
neck lymph node metastases
• Poorly differentiated
• Consider for prior radiation
exposure (category 2B)
Consider for bilateral nodularity
After lobectomy completion thyroidectomy plus ND
Any of the following:
• Tumor >4 cm
• Gross positive resection
margins
• Gross extra-thyroidal extension
• Confirmed nodal metastasis
• Confirmed contralateral disease
• Vascular invasion
• Poorly differentiated
After lobectomy surveillance
All of the following:
• Negative resection margins
• No contralateral lesion
• Tumor <1 cm in diameter
• No suspicious lymph node
or
• NIFTP
Any of- lymphovasc or multiple micro either completion or surveilance
Completion thyroidectomy not done in
Central node <5 nodes none more than 2 mm
RAI INDICATION
Gross ETE
Tr> 4 cm
Postop unstimulated Tg >10 ng
Bulky or >5 positive lymph nodes
Known or suspected distant mets at presentation
RAI not recommended
If all present
Classic papillary thyroid carcinoma (PTC)
• Largest primary tumor <2 cm
• Intrathyroidal
• Unifocal or multifocal (all foci $1 cm)
• No detectable anti-Tg antibodies
• Postoperative unstimulated g <1 ng/mL
• Negative postoperative ultrasound, if done°
High risk pathology dtc
Tall cell
Insular
Diffuse sclerosing
Mucinous
Pd
Hobnail
Columnar
Dtc cut off of tg no more inv
<2
Systemic therapy for dtc
Lenvatenib
NTRK GENE +
Larotrectinib entrectinib
Ret postive thy CA meds
Selperactinib
Pralsetinib
High tumor mutational burden thy CA mab
Pembrolizumab
• Minimally invasive FTC is
Encapsulated
Microscopic capsular invasion
Ftc lobectomy when
Less than 4 vesels encapsulated angioinvasive and minimally invasive
RAi ftc
RAl recommended (if any preseni):
• Gross extrathyroidal extension
• Primary tumor >4 cm
• Extensive vascular invasiond
• Postoperative unstimulated Tg > 10 ng/LI,n
• Bulky or >5 positive lymph nodes
Rai ftc not recommended
RAI not typically recommended (if all present):
• Largest primary tumor <2 cm
• Intrathyroidal
• No vascular invasion
• Clinical NO
• No detectable anti-Tg antibodies
• Postoperative unstimulated g <1 ng/mL!
• Negative postoperative ultrasound, if donem
Imaging ct etc in mtc when calcitonin > than
400
Men2 prophylactic level 2-5 dissection done when
2b age 1 -tt
2-5 if tr more than 0.5 cm
2a age 5-tt
If cn +
Or tr>1 cm
ELND NOT DONE WHEN CALCITONIN
400
2 m Postop ct neck liver chest if calcitonin >
150
Drugs mtc
Vandetanib
Cabozatenib
Ret+- selpercatenib, pralsetinib
Anaplastic
Pet scan done
All are tested in ATC
• RET
• ALK
• NTRK
• dMMR
Msi
Braf
Tumor burden
Neoadjuvant thyca
Vandetanib
Lenvatenib
Cabozatinib
Adjuct Ct thy
Done in all ebrt imrt
Paclitaxel carbo
docetaxel doxo
Cisplatin
Doxorubicin
Imatinib also